Detalhe da pesquisa
1.
Romosozumab and antiresorptive treatment: the importance of treatment sequence.
Osteoporos Int
; 33(6): 1243-1256, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35165774
2.
Correction to: Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
J Bone Miner Metab
; 38(4): 605, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32198616
3.
Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
J Bone Miner Metab
; 38(3): 310-315, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707465
4.
Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
N Engl J Med
; 375(16): 1532-1543, 2016 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27641143
5.
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
N Engl J Med
; 373(14): 1318-28, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26422722
6.
Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
Value Health
; 20(8): 1174-1179, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28964451
7.
Clinical meaningfulness of complete skin clearance in psoriasis.
J Am Acad Dermatol
; 75(1): 77-82.e7, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27206759
8.
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis.
J Am Acad Dermatol
; 72(3): 436-439.e1, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25553889
9.
Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment.
J Am Acad Dermatol
; 71(6): 1183-1190.e3, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25313095
10.
Improving resource utilisation in SLE drug development through innovative trial design.
Lupus Sci Med
; 10(2)2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37491104
11.
The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study.
JBMR Plus
; 3(10): e10211, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31687647
12.
One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
J Bone Miner Res
; 34(3): 419-428, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30508316
13.
Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome.
J Bone Miner Res
; 33(8): 1407-1416, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29750828
14.
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.
J Bone Miner Res
; 33(7): 1219-1226, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29573473
15.
Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis.
J Dermatolog Treat
; 26(3): 235-9, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25078334